Mock J - Search Results

1

A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.

Galbiati A, Zana A, Bocci M, Millul J, Elsayed A, Mock J, Neri D, Cazzamalli S. Galbiati A, et al. Among authors: mock j. J Nucl Med. 2022 Dec;63(12):1852-1858. doi: 10.2967/jnumed.122.264036. Epub 2022 May 19. J Nucl Med. 2022. PMID: 35589404 Free PMC article.

2

A universal reporter cell line for bioactivity evaluation of engineered cytokine products.

Mock J, Pellegrino C, Neri D. Mock J, et al. Sci Rep. 2020 Feb 24;10(1):3234. doi: 10.1038/s41598-020-60182-4. Sci Rep. 2020. PMID: 32094407 Free PMC article.

3

Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors.

Mortensen MR, Mock J, Bertolini M, Stringhini M, Catalano M, Neri D. Mortensen MR, et al. Among authors: mock j. Oncotarget. 2020 Nov 3;11(44):3972-3983. doi: 10.18632/oncotarget.27772. eCollection 2020 Nov 3. Oncotarget. 2020. PMID: 33216834 Free PMC article.

4

An engineered 4-1BBL fusion protein with "activity on demand".

Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. Mock J, et al. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31780-31788. doi: 10.1073/pnas.2013615117. Epub 2020 Nov 25. Proc Natl Acad Sci U S A. 2020. PMID: 33239441 Free PMC article.

5

Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.

Stringhini M, Mock J, Fontana V, Murer P, Neri D. Stringhini M, et al. Among authors: mock j. MAbs. 2021 Jan-Dec;13(1):1868066. doi: 10.1080/19420862.2020.1868066. MAbs. 2021. PMID: 33404287 Free PMC article.

6

Cancer therapy in mice using a pure population of CD8⁺ T cell specific to the AH1 tumor rejection antigen.

Stringhini M, Spadafora I, Catalano M, Mock J, Probst P, Spörri R, Neri D. Stringhini M, et al. Among authors: mock j. Cancer Immunol Immunother. 2021 Nov;70(11):3183-3197. doi: 10.1007/s00262-021-02912-9. Epub 2021 Apr 1. Cancer Immunol Immunother. 2021. PMID: 33796916 Free PMC article.

7

An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications.

Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, Dakhel Plaza S, Nadal L, Gloger A, Schmidt E, Biancofiore I, Donckele EJ, Samain F, Neri D, Cazzamalli S. Millul J, et al. Among authors: mock j. Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2101852118. doi: 10.1073/pnas.2101852118. Proc Natl Acad Sci U S A. 2021. PMID: 33850024 Free PMC article.

8

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.

Dakhel S, Lizak C, Matasci M, Mock J, Villa A, Neri D, Cazzamalli S. Dakhel S, et al. Among authors: mock j. Int J Mol Sci. 2021 Sep 16;22(18):10020. doi: 10.3390/ijms221810020. Int J Mol Sci. 2021. PMID: 34576184 Free PMC article.

9

An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties.

Di Nitto C, Gilardoni E, Mock J, Nadal L, Weiss T, Weller M, Seehusen F, Libbra C, Puca E, Neri D, De Luca R. Di Nitto C, et al. Among authors: mock j. Pharmaceutics. 2023 Jan 22;15(2):377. doi: 10.3390/pharmaceutics15020377. Pharmaceutics. 2023. PMID: 36839699 Free PMC article.

10

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.

Elsayed A, Pellegrino C, Plüss L, Peissert F, Benz R, Ulrich F, Thorhallsdottir G, Plaza SD, Villa A, Mock J, Puca E, De Luca R, Manz MG, Halin C, Neri D. Elsayed A, et al. Among authors: mock j. MAbs. 2023 Jan-Dec;15(1):2220839. doi: 10.1080/19420862.2023.2220839. MAbs. 2023. PMID: 37288872 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters